• In April 2026, Marsh & McLennan Companies reported first-quarter 2026 results showing sales of US$7,597 million, net income of US$1,146 million, and lower earnings per share year over year, alongside confirmation that it completed a US$1,074.65 million buyback covering 1.23% of shares since November 2025.
• While revenue increased compared with the prior year, the combination of declining net income and earnings per share with continued share repurchases highlights a shift in the balance between operational performance and capital return.
• We’ll now consider how this mix of higher revenue, lower earnings, and ongoing buybacks could influence Marsh & McLennan’s investment narrative.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Marsh & McLennan Companies Investment Narrative Recap

To own Marsh & McLennan, you have to believe its global risk and advisory franchise can convert rising complexity in insurance and regulation into steady, fee-based earnings, even as markets evolve. The latest quarter’s higher revenue but lower earnings per share, combined with ongoing buybacks, does not materially change that near term, but it does sharpen the focus on margin resilience as the key catalyst and on soft insurance pricing as a central risk.

The most relevant recent development here is the completion of the US$1,074.65 million buyback, retiring 1.23% of shares since November 2025. For investors, this capital return program now sits alongside slower earnings progression and softer profit margins, making it an important counterweight to risks such as weaker pricing in property and reinsurance and pressure on consulting demand if clients pull back on discretionary projects.

However, investors should be aware that softer pricing in key insurance lines could...

Marsh & McLennan Companies' narrative projects $31.3 billion revenue and $5.6 billion earnings by 2029. This implies 4.4% yearly revenue growth and a $1.7 billion earnings increase from $3.9 billion today.

Uncover how Marsh & McLennan Companies' forecasts yield a $203.67 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community place Marsh & McLennan’s fair value between US$203.43 and US$289.93, highlighting a wide spread of views. You are weighing those opinions against a business where the key near term question is whether rising global risk complexity can offset pressure from softer insurance pricing and margin strain, so it helps to consider several different angles before forming a view.

Explore 3 other fair value estimates on Marsh & McLennan Companies - why the stock might be worth just $203.43!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Marsh & McLennan Companies research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Marsh & McLennan Companies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Marsh & McLennan Companies' overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Find 63 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.